Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Frits van Rhee, MD PhD, Alan Mitchell, Christoph Heuck, MD, Monica Grazziutti, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 1199.

https://doi.org/10.1182/blood.V124.21.1199.1199

Published: 2014

Journal Articles

Ex Vivo Patient-Specific Validation Of Personalized Therapeutic Designed For Multiple Myeloma

Nicole A Doudican, PhD, Shireen Vali, PhD, Shweta Kapoor, Anay Talawdekar, Zeba Sultana, Aftab Alam, Ansu Kumar, Neeraj Kumar Singh, Anuj Tyagi, Taher Abbasi, Amitabha Mazumder, M.D.

Blood (2013) 122 (21): 4219.

https://doi.org/10.1182/blood.V122.21.4219.4219

Published: 2013

Journal Articles

Rb Protects B-Lineage Hematopoietic Progenitor Cells From Oxidative Stress and Exhaustion

Zhiwen He, Yinan Wang, Jun Luo, Lan Lu, MSci, Mack Y. Su, Ravi Vij, MD, Deepta Bhattacharya, PhD, Michael H. Tomasson, MD

Blood (2012) 120 (21): 1315.

https://doi.org/10.1182/blood.V120.21.1315.1315

Published: 2012

Journal Articles

Chromosomal Abnormalities in Bone Marrow Lymphocytes of MM Patients

Carina S. Debes Marun, Andrew Belch, MD, Linda M. Pilarski, PhD

Blood (2010) 116 (21): 4045.

https://doi.org/10.1182/blood.V116.21.4045.4045

Published: 2010

Journal Articles

Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).

Sophie Dupire, Houria Debarri, Laurent Pascal, Valerie Coiteux, Benedicte Hivert, Christophe Willekens, Julien Rossignol, Ibrahim Yakoub-Agha, MD, PhD, Brigitte Onraed, Jean-Luc Faucompré, Bernadette Hennache, Charles Dumontet, Thierry Facon, Xavier Leleu

Blood (2009) 114 (22): 2493.

https://doi.org/10.1182/blood.V114.22.2493.2493

Published: 2009

Journal Articles

8p11–12 Myeloprolferative Syndrome: A Case Report and Brief Review of the Literature

Sarvari Venkata Yellapragada, MD, Martha P. Mims, MD, PhD, Courtney Jackson, MD, Mark Lewis, MD, Mark M. Udden, MD

Blood (2008) 112 (11): 5260.

https://doi.org/10.1182/blood.V112.11.5260.5260

Published: 2008

Journal Articles

Deciphering the Heterogeneity of 13q Deletions in CLL on the Cytogenetic and Molecular Level by SNP Arrays: In 49% of Cases Deletion Breakpoints Cluster in a 200 Kb Sized Region on the Centromeric Side and in a 300 Kb Sized Region on the Telomeric Side

Claudia Haferlach, MD, Alexander Kohlmann, PhD, Sonja Rauhut, Frank Dicker, PhD, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2008) 112 (11): 3147.

https://doi.org/10.1182/blood.V112.11.3147.3147

Published: 2008

Journal Articles

Comparative Genomic Analysis of CLL Genomes Using Affymetrix 50K SNP Versus SNP 6.0 Arrays

Sami Malek, MD, Whitney Wright, Cheng Li, Sajid Shakhan, Peter Ouillette

Blood (2008) 112 (11): 3108.

https://doi.org/10.1182/blood.V112.11.3108.3108

Published: 2008

Journal Articles

Impact of Chromosome 13 Deletion and Plasma Cell Load on Long-Term Survival of Patients with Multiple Myeloma Undergoing Autologous Transplantation

Esbjörn Paul, Tolga Sutlu, Evren Alici, Goesta Gahrton, MD, PhD, Hareth Nahi

Blood (2008) 112 (11): 5148.

https://doi.org/10.1182/blood.V112.11.5148.5148

Published: 2008

Journal Articles

Deletion 13q in B-CLL: Interphase FISH Reveals More 13q- Than Does CpG Stimulation.

Daniel L. Van Dyke, PhD, G.W. Dewald, PhD, T.G. Call, MD, D.F. Jelinek, PhD, C.S. Zent, MD, T.D. Shanafelt, MD, S.A. Smoley, K.J. Stockero, N.E. Kay

Blood (2007) 110 (11): 2070.

https://doi.org/10.1182/blood.V110.11.2070.2070

Published: 2007

Journal Articles

FISH and Chips: Novel, Point of Care Technology To Detect Chromosomal Abnormalities.

Carina S. Debes Marun, Vincent Sieben, Patrick M. Pilarski, Tony Reiman, Andrew R. Belch, Christopher J. Backhouse, Linda M. Pilarski

Blood (2006) 108 (11): 3402.

https://doi.org/10.1182/blood.V108.11.3402.3402

Published: 2006

Journal Articles

Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial.

Nizar J. Bahlis, MD, Adnan Mansoor, MD, Johannes C. Lategan, MD, Karen Valentine, MD, Tedd Thaell, MD, Walter Blahey, MD, Mary Lynn Savoie, MD, Kim Blaikie, RN, Leanne Kmet, PhD, Birgitte Roland, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3557.

https://doi.org/10.1182/blood.V108.11.3557.3557

Published: 2006

Journal Articles

Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).

Michele Cavo, Nicoletta Testoni, Carolina Terragna, Elena Zamagni, Paola Tacchetti, Chiara Nicci, Matteo Renzulli, Elena Montanari, Giulia Perrone, Delia Cangini, Tiziana Grafone, Michela Ceccolini, AnnaMaria Brioli, Giovanni Martinelli, Patrizia Tosi, Michele Baccarani

Blood (2006) 108 (11): 3081.

https://doi.org/10.1182/blood.V108.11.3081.3081

Published: 2006

Journal Articles

Clinical Presentation, Prognostic Factors and Treatment Outcome of Multiple Myeloma (MM) in African American (AA) Patients.

Ashraf Z. Badros, MD, Olga Goloubeva, PhD, Saranya Chumsri, MD, Kathleen Ruehle, RN, Yi Ning, PhD, Joann Meekins, PhD, Liliana Guedez, PhD, Aaron P. Rapoport, MD, Barry Meisenberg, MD, Gorgun Akpek, MD, Saul Yanovich, MD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 5024.

https://doi.org/10.1182/blood.V108.11.5024.5024

Published: 2006

Journal Articles

High Density Oligonucleotide Array CGH Analysis of CLL Reveals Areas of Recurrent Genomic Gain or Loss.

Roelandt F.J. Schop, MD, Catherine Mancini, BS, Wee-Joo Chng, MD, Renee C. Tschumper, BS, Diane F. Jelinek, PhD, Neil E. Kay, MD, Peter Leif Bergsagel, MD, John D. Carpten, PhD, Rafael Fonseca, MD

Blood (2006) 108 (11): 2093.

https://doi.org/10.1182/blood.V108.11.2093.2093

Published: 2006

Journal Articles

A Comparative Analysis of Chromosome 13 Gene Expression and Copy Number Changes in Multiple Myeloma Using Array-Based Methods.

Blood (2005) 106 (11): 1557.

https://doi.org/10.1182/blood.V106.11.1557.1557

Published: 2005

Journal Articles

Status of Chromosome 13 in Multiple Myeloma: Integrated Approach Using SNP Mapping Array and Gene Expression Array.

Paola E. Leone, PhD, Brian A. Walker, PhD, David Gonzalez, PhD, Matthew Jenner, MD, Fiona M. Ross, PhD, Cheng Li, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2005) 106 (11): 1563.

https://doi.org/10.1182/blood.V106.11.1563.1563

Published: 2005

Journal Articles

Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).

Daniel L. Van Dyke, PhD, Kimberly Stockero, Stephanie Fink, Stephanie Smoley, Sarah Paternoster, Susan Schwager, Tait Shanafelt, MD, Clive Zent, MD, Timothy Call, MD, Neil Kay, MD, Gordon Dewald, PhD

Blood (2005) 106 (11): 3278.

https://doi.org/10.1182/blood.V106.11.3278.3278

Published: 2005

Journal Articles

Critical Importance of Conventional Cytogenetics in Detecting Prognostically Significant Chromosome 13 Deletions in Myeloma.

Laura Chiecchio, MBS, Rebecca K.M. Protheroe, BSc, Tim Parker, BSc, Christina Rudduck, PhD, Kan Luk Cheung, BSc, Gianpaolo Dagrada, MBS, Ashutosh Wechalekar, MD, Mathew Nightingale, BSc, Christine J. Harrison, PhD, Nicholas C.P. Cross, PhD, Fiona M. Ross, DPhil

Blood (2005) 106 (11): 1544.

https://doi.org/10.1182/blood.V106.11.1544.1544

Published: 2005

Journal Articles

Circulating B Lymphocytes from Patients with Multiple Myeloma Harbour T(4;14) Translocations and Chromosome 13 Deletions.

Carina Debes-Marun, Andrew R. Belch, MD, Linda M. Pilarski, PhD

Blood (2005) 106 (11): 500.

https://doi.org/10.1182/blood.V106.11.500.500

Published: 2005

NARROW

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Ex Vivo Patient-Specific Validation Of Personalized Therapeutic Designed For Multiple Myeloma

Rb Protects B-Lineage Hematopoietic Progenitor Cells From Oxidative Stress and Exhaustion

Chromosomal Abnormalities in Bone Marrow Lymphocytes of MM Patients

Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).

8p11–12 Myeloprolferative Syndrome: A Case Report and Brief Review of the Literature

Deciphering the Heterogeneity of 13q Deletions in CLL on the Cytogenetic and Molecular Level by SNP Arrays: In 49% of Cases Deletion Breakpoints Cluster in a 200 Kb Sized Region on the Centromeric Side and in a 300 Kb Sized Region on the Telomeric Side

Comparative Genomic Analysis of CLL Genomes Using Affymetrix 50K SNP Versus SNP 6.0 Arrays

Impact of Chromosome 13 Deletion and Plasma Cell Load on Long-Term Survival of Patients with Multiple Myeloma Undergoing Autologous Transplantation

Deletion 13q in B-CLL: Interphase FISH Reveals More 13q- Than Does CpG Stimulation.

FISH and Chips: Novel, Point of Care Technology To Detect Chromosomal Abnormalities.

Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial.

Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).

Clinical Presentation, Prognostic Factors and Treatment Outcome of Multiple Myeloma (MM) in African American (AA) Patients.

High Density Oligonucleotide Array CGH Analysis of CLL Reveals Areas of Recurrent Genomic Gain or Loss.

A Comparative Analysis of Chromosome 13 Gene Expression and Copy Number Changes in Multiple Myeloma Using Array-Based Methods.

Status of Chromosome 13 in Multiple Myeloma: Integrated Approach Using SNP Mapping Array and Gene Expression Array.

Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).

Critical Importance of Conventional Cytogenetics in Detecting Prognostically Significant Chromosome 13 Deletions in Myeloma.

Circulating B Lymphocytes from Patients with Multiple Myeloma Harbour T(4;14) Translocations and Chromosome 13 Deletions.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only